Protara Therapeutics (NASDAQ:TARA) Upgraded at Piper Sandler

Protara Therapeutics (NASDAQ:TARA) was upgraded by research analysts at Piper Sandler to a “strong-buy” rating in a report released on Wednesday,Zacks.com reports.

A number of other equities research analysts have also weighed in on TARA. HC Wainwright reiterated a “buy” rating and issued a $23.00 price objective on shares of Protara Therapeutics in a research report on Wednesday, December 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Protara Therapeutics in a report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $20.40.

Protara Therapeutics Trading Down 1.4%

TARA stock opened at $5.61 on Wednesday. The stock has a market capitalization of $289.64 million, a price-to-earnings ratio of -3.92 and a beta of 1.42. The firm’s 50-day moving average price is $5.75 and its two-hundred day moving average price is $4.39. Protara Therapeutics has a 12-month low of $2.77 and a 12-month high of $7.82.

Protara Therapeutics (NASDAQ:TARA) last posted its earnings results on Monday, November 10th. The company reported ($0.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.08. Equities analysts predict that Protara Therapeutics will post -3.32 EPS for the current year.

Institutional Trading of Protara Therapeutics

A number of hedge funds have recently modified their holdings of TARA. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Protara Therapeutics in the 2nd quarter worth about $30,000. Quadrature Capital Ltd bought a new stake in Protara Therapeutics during the second quarter worth about $35,000. JPMorgan Chase & Co. purchased a new stake in Protara Therapeutics in the second quarter worth about $46,000. Los Angeles Capital Management LLC bought a new position in shares of Protara Therapeutics during the second quarter valued at approximately $47,000. Finally, Intech Investment Management LLC bought a new position in shares of Protara Therapeutics during the second quarter valued at approximately $49,000. Institutional investors own 38.13% of the company’s stock.

About Protara Therapeutics

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.